标题
Mineralocorticoid Antagonism and Diabetic Kidney Disease
作者
关键词
Mineralocorticoid receptor antagonist, Diabetes, Diabetic kidney disease
出版物
Current Diabetes Reports
Volume 19, Issue 1, Pages -
出版商
Springer Nature
发表日期
2019-02-07
DOI
10.1007/s11892-019-1123-8
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Chronic Kidney Disease in Diabetes
- (2018) Philip McFarlane et al. Canadian Journal of Diabetes
- Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice
- (2018) Benjamin Bonnard et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury–Mediated Chronic Kidney DiseaseNovelty and Significance
- (2017) Lionel Lattenist et al. HYPERTENSION
- Population Pharmacokinetics of LY2623091 in Patients With Hypertension and Chronic Kidney Disease
- (2017) Evan B. Wang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1
- (2017) Jonatan Barrera-Chimal et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- New and old agents in the management of diabetic nephropathy
- (2016) Yuliya Lytvyn et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON
- (2016) Muh Geot Wong et al. DIABETES CARE
- Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants
- (2016) LANCET
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Additive Therapy With Spironolactone on Proteinuria in Diabetic Patients Already on ACE Inhibitor or ARB Therapy
- (2016) Mohammad G. Saklayen et al. JOURNAL OF INVESTIGATIVE MEDICINE
- Nonsteroidal antagonists of the mineralocorticoid receptor
- (2015) Peter Kolkhof et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease
- (2015) Bertram Pitt et al. EUROPEAN JOURNAL OF HEART FAILURE
- Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease
- (2015) Peter Bramlage et al. EUROPEAN JOURNAL OF HEART FAILURE
- New data do not SUPPORT triple RAAS blockade
- (2015) A. H. Jan Danser et al. Nature Reviews Nephrology
- Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
- (2015) Matthew R. Weir et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With Hyperkalemia
- (2014) Mikhail Kosiborod et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Targeting Cardiac Hypertrophy
- (2014) Egbert Bisping et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Renal Outcomes in Patients with Type 1 Diabetes and Macroalbuminuria
- (2014) I. H. de Boer et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease
- (2013) Regina Kunz et al. ANNALS OF INTERNAL MEDICINE
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
- (2013) Linda F. Fried et al. NEW ENGLAND JOURNAL OF MEDICINE
- PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
- (2013) Stephen Orena et al. Frontiers in Pharmacology
- KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
- (2012) AMERICAN JOURNAL OF KIDNEY DISEASES
- Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease
- (2012) Bertram Pitt et al. EUROPEAN JOURNAL OF HEART FAILURE
- Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease
- (2012) Ravi Thadhani et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases
- (2012) E. Morales et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
- (2012) Hans-Henrik Parving et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intestinal Necrosis Associated with Orally Administered Calcium Polystyrene Sulfonate without Sorbitol
- (2011) Philippe Goutorbe et al. ANNALS OF PHARMACOTHERAPY
- Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes
- (2011) Hermann Haller et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats
- (2009) Bing S. Huang et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis
- (2009) G. M. Magee et al. DIABETOLOGIA
- Antifibrotic Effects of Aldosterone Receptor Blocker (Spironolactone) in Patients with Chronic Kidney Disease
- (2009) Ibrahim Guney et al. RENAL FAILURE
- Change in Proteinuria After Adding Aldosterone Blockers to ACE Inhibitors or Angiotensin Receptor Blockers in CKD: A Systematic Review
- (2008) Andrew S. Bomback et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Triple Pharmacological Blockade of the Renin-Angiotensin-Aldosterone System in Nondiabetic CKD: An Open-Label Crossover Randomized Controlled Trial
- (2008) Leszek Tylicki et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Effect of Renin-Angiotensin-Aldosterone System Triple Blockade on Non-Diabetic Renal Disease: Addition of an Aldosterone Blocker, Spironolactone, to Combination Treatment with an Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker
- (2008) Yoshiyuki FURUMATSU et al. HYPERTENSION RESEARCH
- Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial
- (2008) Johannes FE Mann et al. LANCET
- Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now